Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of fordadistrogene movaparvovec in Duchenne muscular dystrophy
NCT05689164Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Mar 2023
- Primary completion
- Sep 2025
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 3 trial of fordadistrogene movaparvovec in Duchenne muscular dystrophy (DMD), sponsored by Pfizer. Started Mar 2023; status: terminated.
02
Drugs
fordadistrogene movaparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05689164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05689164.